A registrational study assessing Apabetalone
Latest Information Update: 15 Jan 2021
At a glance
- Drugs Apabetalone (Primary)
- Indications Cardiovascular disorders
- Focus Registrational; Therapeutic Use
- Acronyms BETonMACE2
Most Recent Events
- 12 Jan 2021 According to a Resverlogix Corporation media release, the company will be including hospitalizations for heart failure in the composite primary endpoint in this study in agreement with the US Food and Drug Administration (FDA) following receipt of the Breakthrough Therapy Designation.
- 29 Jun 2020 New trial record
- 28 Jun 2020 According to a Resverlogix Corporation media release, Filing of a New Drug Application (NDA) with the FDA is possible following unequivocal efficacy at an interim analysis of BETonMACE2